Recent findings in phosphate homeostasis

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 4, 2005, Pages 318-324

  Prié, Dominique ^a,b   Beck, Laurent ^a   Urena, Pablo ^a,b,c   Friedlander, Gérard ^a,b,d  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Clinique de l'Orangerie Aubervilliers   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Calcitriol; Fibroblast growth factor 23; Intestine; Kidney; Lifespan; Phosphate

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE TRANSPORTER; PROTEIN; PROTEIN NPT2A; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM PHOSPHATE COTRANSPORTER; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

AGING; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; DNA POLYMORPHISM; GENE; GENE DISRUPTION; GENE MUTATION; HORMONAL REGULATION; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KLOTHO GENE; LIFESPAN; METABOLIC REGULATION; NONHUMAN; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PHOSPHATURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RICKETS; SURVIVAL; TUMOR CALCINOSIS;

EID: 20844440018     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000172716.41853.1e     Document Type: Review

References (86)

1. Cheret C, Doyen A, Yaniv M, et al. Hepatocyte nuclear factor 1 alpha controls renal expression of the Npt1 - Npt4 anionic transporter locus. J Mol Biol 2002; 322:929-941.
2. Melis D, Havelaar AC, Verbeek E, et al. NPT4, a new microsomal phosphate transporter: mutation analysis in glycogen storage disease type Ic. J Inherit Metab Dis 2004; 27: 725-733.
3. Collins JF, Bai L, Ghishan FK. The SLC20 family of proteins: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch 2004; 447:647-652. A recent review on type 1 and 2 inorganic phosphate transporters.
4. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086.
5. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497-500.
6. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15:2959-2964.
7. Wada K, Mizuno M, Komori T, et al. Extracellular inorganic phosphate regulates gibbon ape leukemia virus receptor-2/phosphate transporter mRNA expression in rat bone marrow stromal cells. J Cell Physiol 2004; 198:40-47. This paper shows that the type 2 Pi transporter but not type 1 expression is modulated by extracellular phosphate concentration.
8. Murer H, Hernando N, Forster I, et al. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80:1373-1409.
9. Gupta A, Tenenhouse HS, Hoag HM, et al. Identification of the type II Na(+) - Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice. Bone 2001; 29:467-476.
10. Beck L. Karaplis AC, Amizuka N, et al. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 1998; 95:5372-5377.
11. Prie D, Huart V, Bakouh N, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347:983-991.
12. Prie D, Beck L, Friedlander G, et al. Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization. Curr Opin Nephrol Hypertens 2004; 13:675-681. The authors present and discuss recent data regarding the mechanisms and the consequences of increased renal phosphate excretion on urolithiasis formation and bone demineralization.
13. Wade JB, Liu J, Coleman RA, et al. Localization and interaction of NHERF isoforms in the renal proximal tubule of the mouse. Am J Physiol Cell Physiol 2003; 285:C1494-C1503.
14. Gisler SM, Stagljar I, Traebert M, et al. Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. J Biol Chem 2001; 276:9206-9213.
15. Hernando N, Deliot N, Gisler SM, et al. PDZ-domain interactions and apical expression of type IIa Na/P(i) cotransporters. Proc Natl Acad Sci U S A 2002; 99:11957-11962.
16. Shenolikar S, Voltz JW, Minkoff CM, et al. Targeted disruption of the mouse NHERF-1 gene promotes internalization of proximal tubule sodium-phosphate cotransporter type IIa and renal phosphate wasting. Proc Natl Acad Sci U S A 2002; 99:11470-11475.
17. Mahon MJ, Donowitz M, Yun CC, et al. Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 2002; 417:858-861.
18. Mahon MJ, Segre GV. Stimulation by parathyroid hormone of a NHERF-1-assembled complex consisting of the parathyroid hormone I receptor, phospholipase Cbeta, and actin increases intracellular calcium in opossum kidney cells. J Biol Chem 2004; 279:23550-23558.
19. Mahon MJ, Cole JA, Lederer ED, et al. Na+/H+ exchanger-regulatory factor 1 mediates inhibition of phosphate transport by parathyroid hormone and second messengers by acting at multiple sites in opossum kidney cells. Mol Endocrinol 2003; 17:2355-2364.
20. Bachmann S, Schlichting U, Geist B, et al. Kidney-specific inactivation of the megalin gene impairs trafficking of renal inorganic sodium phosphate cotransporter (NaPi-IIa). J Am Soc Nephrol 2004; 15:892-900. This study shows that the control of NPT2a expression by PTH requires the presence of megalin. In megalin knockout mice PTH administration fails to stimulate NPT2a retrieval from the proximal BBM.
21. Tenenhouse HS, Martel J, Gauthier C, et al. Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol 2003; 285:F1271-F1278.
22. Ohkido I, Segawa H, Yanagida R, et al. Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflugers Arch 2003; 446:106-115.
23. Segawa H, Yamanaka S, Ito M, et al. Internalization of renal type IIc Na-Pi cotransporter in response to a high-phosphate diet. Am J Physiol Renal Physiol 2005; 288:F587-F596. This is the first report that type 2c renal phosphate transporter expression is regulated by phosphate diet.
24. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1 (I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004; 145:3087-3094. Overexpression of wild type FGF-23 in osteoblastic cells in mice decreases expression of sodium phosphate cotransporters in the kidney, induces bone abnormalities and secondary hyperparathyroidism.
25. Hilfiker H, Hattenhauer O, Traebert M, et al. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci U S A 1998; 95: 14564-14569.
26. Xu H, Bai L, Collins JF, et al. Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). Genomics 1999; 62:281-284.
27. Katai K, Miyamoto K, Kishida S, et al. Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. Biochem J 1999; 343(Pt 3):705-712.
28. Xu H, Bai L, Collins JF, et al. Age-dependent regulation of rat intestinal type IIb sodium-phosphate cotransporter by 1,25-(OH)(2) vitamin D(3). Am J Physiol Cell Physiol 2002; 282:C487-C493.
29. Palmada M, Dieter M, Speil A, et al. Regulation of intestinal phosphate cotransporter NaPi IIb by ubiquitin ligase Nedd4-2 and by serum- and glucocorticoid-dependent kinase 1. Am J Physiol Gastrointest Liver Physiol 2004; 287:143-150. This paper presents a novel regulation pathway of NPT2b. Activation of serum and glucocorticoid-inducible kinase 1, a kinase induced by various factors including glucocorticoids, stimulates NPT2b activity by inhibiting the ubiquitination process.
30. Staub O, Yeger H, Plant PJ, et al. Immunolocalization of the ubiquitin-protein ligase Nedd4 in tissues expressing the epithelial Na+ channel (ENaC). Am J Physiol Cell Physiol 1997; 272:C1871-C1880.
31. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98:6500-6505.
32. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960.
33. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278:2206-2211.
34. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409-414. Overexpression of FGF-23 decreases type 2a sodium phosphate cotransporter protein in the kidney independently of PTH action.
35. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435. This paper describes the time course of FGF-23 consequences on renal phosphate reabsorption and calcitriol homeostasis. FGF-23 injection decreases renal phosphate transport and sodium phosphate cotransporter expression even in the absence of PTH. The effect of FGF-23 on calcitriol concentration precedes hypophosphatemia. Calcitriol injection increases serum FGF-23 concentrations.
36. Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145:5269-5279. Overexpression in the liver of a mutant FGF-23 resistant to proteases decreases renal phosphate reabsorption, bone mineralization and induces secondary hyperparathyroidism.
37. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568. A very interesting paper that describes the phenotype of mice in which the FGF-23 gene has been selectively disrupted. Some phenotypic features remain incompletely understood.
38. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90:1519-1524. An elegant study that gives evidence that FGF-23 is a hormone that regulates phosphate homeostasis under physiological conditions in healthy individuals.
39. Gupta A, Winer K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 2004; 89:4489-4492. The authors show that FGF-23 levels are increased in patients with chronic hypoparathyroidism, suggesting that hyperphosphataemia stimulates FGF-23 production.
40. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280:2543-2549. This paper provides evidence that calcitriol by itself, independently of variations of serum phosphate concentration, stimulates FGF-23 production. Injection of calcitriol in thyroparathyroidectomized rats increases plasma FGF-23 concentrations and decreases serum phosphate concentration in a dose-dependent manner.
41. Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K562 cells. Am J Physiol Endocrinol Metab 2005; 25 January [Epub ahead of print]. This paper confirms that calcitriol by itself inhibits FGF-23 production.
42. Yamashita T, Konishi M, Miyake A, et al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277:28265-28270.
43. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26:345-348.
44. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278:37419-37426.
45. Mirams M, Robinson BG, Mason RS, et al. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35:1192-1199. The authors measured FGF-23 mRNA expression in various tissues and concluded that bone may be the main source of FGF-23 production and that extracellular phosphate concentration regulates FGF-23 synthesis in bone.
46. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179-3182.
47. Bai XY, Miao D, Goltzman D, et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003; 278:9843-9849.
48. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11:130-136.
49. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001; 284:977-981.
50. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663.
51. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581. This is the first identification of mutations in the GALNT3 gene in families exhibiting hyperphosphataemia and calcification of soft tissues. The authors studied the sites of expression of GALNT3 and FGF-23 and discuss the relation between these two proteins.
52. Ichikawa S, Lyles KW, Econs MJ. A novel GALNT3 mutation in a pseudo-autosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 2005; 1 February [Epub ahead of print]. One of the two papers that identified GALNT3 mutations as responsible for tumoral calcinosis. The authors studied the expression of GALNT3 and FGF-23 in various tissues and discuss the role of GALNT3 on FGF-23 activity.
53. Benet-Pages A, Orlik P, Strom TM, et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390. Patients with tumoral calcinosis exhibit a phenotype reminiscent of that observed in mice with targeted ablation of FGF-23 gene. The authors identified a mutation in the FGF-23 gene and show that only the C-terminal fragment of FGF-23 is secreted while intact FGF-23 is retained in the Golgi apparatus.
54. Larsson T, Yu X, Davis SI, et al. A novel recessive mutation in fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005; 1 February [Epub ahead of print]. The authors identified a mutation in the FGF-23 gene in a family affected by tumoral calcinosis. The mutation destabilizes the FGF-23 protein leading to high C-terminal and tow intact circulating FGF-23 peptides.
55. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279.
56. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65:1943-1946. The authors measured circulating FGF-23 concentration in hemodialysis patients and analysed the correlation with the parameters of calcium phosphate metabolism.
57. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44:250-256. The authors show that in humans, circulating FGF-23 concentrations increase with the decline in renal function and may be responsible for the hyperparathyroidism observed in patients by decreasing plasma calcitriol levels.
58. Weber TJ, Liu S, Indridason OS, et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18:1227-1234.
59. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67:1171-1178. The authors show that the best predictor of the occurrence of refractory hyperparathyroidism in haemodialysis patients is the FGF-23 levels. Extremely high plasma FGF-23 levels may precede refractory hyperparathyroidism by 2 years, suggesting that FGF-23 measurements may be relevant to the management of haemodialysis patients.
60. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51.
61. Morishita K, Shirai A, Kubota M, et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001; 131:3182-3188.
62. Tsujikawa H, Kurotaki Y, Fujimori T, et al. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17:2393-2403.
63. Matsumura Y, Aizawa H, Shiraki-lida T, et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998; 242:626-630.
64. Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 2004; 565:143-147. This paper reports the molecular characterization of the different forms of Klotho proteins, sizes, sites of expression.
65. Xiao NM, Zhang YM, Zheng Q, et al. Klotho is a serum factor related to human aging. Chin Med J (Engl) 2004; 117:742-747. The authors show that the levels of circulating Klotho protein decrease while age increases in humans with no difference in sex.
66. Tohyama O, Imura A, Iwano A, et al. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004; 279:9777-9784.
67. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003; 112:785-794.
68. Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004; 34:303-319. This paper presents evidences that MERE inhibits phosphate uptake in renal proximal tubular cells and that this property is localized to the carboxy-terminal extremity of the protein.
69. Carpenter TO, Ellis BK, Insogna KL, et al. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005; 90:1012-1020. The authors identified a new phosphaturic agent and show that it is a potent inhibitor of phosphate uptake by proximal tubular cells.
70. Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 2004; 131:5103-5115. This paper provides new insights into the mechanism by which Wnt activates signaling in cells.
71. Wang HY, Malbon CC. Wnt signaling, Ca2+, and cyclic GMP: visualizing Frizzled functions. Science 2003; 300:1529-1530.
72. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000; 67:54-68.
73. Argiro L, Desbarats M, Glorieux FH, et al. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia is expressed in bone. Genomics 2001; 74:342-351.
74. Bresler D, Bruder J, Mohnike K, et al. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 2004; 183:R1-R9. The authors show new data that modify our understanding of the mechanisms of phosphate disorders in X-linked hypophosphataemia. The plasma concentration of ASARM peptides, derived from the carboxy terminal extremity of MEPE, are elevated in XLH patients and in the animal counterpart hyp mice.
75. Guo R, Rowe PS, Liu S, et al. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 2002; 297:38-45.
76. Rowe PS, Garrett IR, Schwarz PM, et al. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 2005; 36:33-46. The authors show that MEPE can bind to Phex and may protect MEPE from proteolysis, preventing the release of the phosphaturic carboxy-terminal peptide. The authors present a convincing model of the pathogenesis of the disorders observed in Phex mutations.
77. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-617.
78. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-1483.
79. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12:2131-2138.
80. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:695-701.
81. Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15:770-779. The authors analyse the association between abnormal phosphate calcium metabolism and mortality in dialysis patients.
82. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520-528. This paper shows that in patients with chronic kidney disease but who do not require haemodialysis, even modest increases in serum phosphate concentration increase the mortality risk.
83. Arking DE, Krebsova A, Macek M Sr, et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A 2002; 99:856-861.
84. Arking DE, Becker DM, Yanek LR, et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003; 72:1154-1161.
85. Bektas A, Schurman SH, Sharov AA, et al. Klotho gene variation and expression in 20 inbred mouse strains. Mamm Genome 2004; 15:759-767. The authors looked for polymorphisms in mouse Klotho gene and found one associated with higher levels of mRNA and Klotho protein and with longer lifespan in mice.
86. Arking DE, Atzmon G, Arking A, et al. Association between the functional variant of KLOTHO allele and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 2005; 96:412-418. The authors performed cross-sectional and prospective studies and found an association between the alleles of a functional variant of Klotho and longevity and cardiovascular events.